## Amendments to the Claims

1. (Cancelled)

2. (Currently Amended) The compound according to ~~Claim 1~~Claim 22 wherein the A-ring is selected from the group consisting of phenyl, pyridine, pyrimidine and pyrazine.

3. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein the C-ring is selected from the group consisting of phenyl and pyridine.

4. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein the A-ring is phenyl and the C ring is pyridine.

5. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein both A and C rings are phenyl.

6. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein p is 2 and both $R^a$ and $R^b$ are hydrogen.

7. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein ~~$-(CR^aR^b)_p-$ equals~~ $(CR^aR^b)_p$ is –CH=CH-.

8. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein E is an oxygen atom.

9. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein y is 0 or 1, and $R^4$ is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, benzyl and ethoxy.

10. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein z is 0 or 1, and $R^5$ is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, and benzyl.

11. (Cancelled)

12. (Currently Amended) The compound according to ~~Claim 1~~Claim 22 wherein $R^6$ and $R^7$ are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and phenyl.

13. (Currently Amended) A compound according to ~~Claim 1~~Claim 22 wherein E is an oxygen atom, wherein both $R^6$ and $R^7$ are hydrogen atoms.

14. (Currently Amended) A compound selected from the group consisting of:
8-[(3-Methyl-butylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-(Isobutylamino-methyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(4-Methyl-pentylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(2-Thiophen-2-yl-ethylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-Pentylaminomethyl-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-Hexylaminomethyl-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(Cyclohexylmethyl-amino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-Cyclooctylaminomethyl-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-Cycloheptylaminomethyl-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(Cycloheptylmethyl-amino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide trifluoroacetate salt,
8-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(3,3-Dimethyl-butylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(2-Cyclopentyl-ethylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(3-Morpholin-4-yl-propylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,

8-[(3-Ethoxy-propylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(2-Diethylamino-ethylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(3-Methoxy-propylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide, and
8-[(3-Phenyl-propylamino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-(3-Phenyl-pyrrolidin-1-ylmethyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-(3-Phenyl-piperidin-1-ylmethyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[2-(4-Chloro-phenyl)-pyrrolidin-1-ylmethyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-(2-Phenyl-pyrrolidin-1-ylmethyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-(2-Phenyl-piperidin-1-ylmethyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-(2-Phenyl-azepan-1-ylmethyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-(2-Benzyl-pyrrolidin-1-ylmethyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide,
8-[(3-Methyl-butylamino)-methyl]-dibenzofuran-2-carboxylic acid amide,
8-[(3-Methyl-butylamino)-methyl]-10,11-dihydro-dibenzo[*b,f*]oxepine-2-carboxilic acid amide,
8-[(3-Methyl-butylamino)-methyl]-10,11-dihydro-5-oxa-4-aza-dibenzo[a,d]cycloheptene-2-carboxylic acid amide,
8-[(3-Methyl-butylamino)-methyl]-5-oxa-4-aza-dibenzo[a,d]cycloheptene-2-carboxylic acid amide,
or a pharmaceutically acceptable salt~~, solvate, enantiomer, diastereomer and diastereomeric mixture~~or solvate thereof.

15. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of ~~formula I~~Claim 22, or a pharmaceutically acceptable salt~~, enantiomer, racemate, mixture of diastereomers,~~ or solvate thereof in association with a carrier, diluent and/or excipient.

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (New) A compound of formula (I)




wherein:

j is 1 or 2;

y is 0, 1, or 2; and z is 0, 1, or 2;

p is 0, 1, or 2;

E is O or NH; and wherein each of

$X_1$, $X_2$, $X_3$, $X_4$, $X_5$, or $X_6$, is C, CH, or N; provided that each of rings A or C has no more than 2 nitrogen atoms; and provided that Ring B has 0 or 1 double bond excluding tautomeric bonds from rings A and C;

$R^1$ and $R^2$ are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, 2-methylpentyl, t-butyl, cyclopropyl, phenyl,



and wherein $R^1$ and $R^2$ may optionally combine with each other to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen -containing heterocycle may further have substituents selected from the group consisting of oxo, amino, $C_1$-$C_8$ alkyl, $C_2$-$C_8$ alkenyl, $C_2$-$C_8$ alkynyl, phenyl, $C_1$-$C_8$ alkylaryl, $C(O)C_1$-$C_8$ alkyl, $CO(O)C_1$-$C_8$ alkyl, halo, $C_1$-$C_8$ haloalkyl;

$R^3$ and $R^{3'}$ are each independently selected from hydrogen, $C_1$-$C_8$ alkyl, $C_2$-$C_8$ alkenyl, $C_2$-$C_8$ alkynyl, phenyl, aryl, $C_1$-$C_8$ alkylcycloalkyl, and $C_1$-$C_8$ alkylaryl;

$R^a$ and $R^b$ are each independently selected from hydrogen, and $C_1$-$C_3$ alkyl or combine with their respective carbon atoms to form the vinyl diradical -CH=CH-;

$R^4$ and $R^5$ are each independently selected from hydrogen, $C_1$-$C_8$ alkyl, $C_2$-$C_8$ alkenyl, $C_2$-$C_8$ alkynyl, $C_1$-$C_8$ alkoxy, halo, $C_1$-$C_8$ haloalkyl, phenyl, aryl, $C_1$-$C_8$ alkylaryl, $(CH_2)_mNSO_2C_1$-$C_8$ alkyl, $(CH_2)_mNSO_2$phenyl, $(CH_2)_mNSO_2$aryl, $-C(O)C_1$-$C_8$ alkyl, and $-C(O)OC_1$-$C_8$ alkyl; wherein each $R^4$ and $R^5$ is attached to its respective ring only at carbon atoms; wherein m is 1 or 2; and n is 1, 2, or 3;

$R^6$ and $R^7$ are each independently selected from hydrogen, $C_1$-$C_8$ alkyl, $C_2$-$C_8$ alkenyl, $C_2$-$C_8$ alkynyl, $C(O)C_1$-$C_8$ alkyl, $SO_2C_1$-$C_8$ alkyl, $SO_2C_1$-$C_8$ alkylaryl, $SO_2C_1$-$C_8$ alkylheterocyclic, aryl, $C_1$-$C_8$ alkylaryl, $C_3$-$C_7$ cycloalkane, $C_1$-$C_6$ alkylcycloalkane, $(CH_2)_nC(O)OR^8$, $(CH_2)_nC(O)R^8$, $(CH_2)_mC(O)NR^8R^8$, and $(CH_2)_mNSO_2R^8$; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to five groups independently selected

from $C_1$-$C_8$ alkyl, $C_2$-$C_8$ alkenyl, phenyl, and $C_1$-$C_8$ alkylaryl; and wherein $R^6$ and $R^7$ may independently combine with each other, and with the nitrogen atom to which they are attached to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may optionally have substituents selected from the group consisting of oxo, amino, $C_1$-$C_8$ alkyl, $C_2$-$C_8$ alkenyl, $C_2$-$C_8$ alkynyl, phenyl, and $C_1$-$C_8$ alkylaryl;
$R^8$ is independently selected from hydrogen, $C_1$-$C_8$ alkyl, $C_2$-$C_8$ alkenyl, phenyl, benzyl, and $C_5$-$C_8$ alkylaryl;
or a compound selected from 8-cyclooctylaminomethyl-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide; 8-cycloheptylaminomethyl-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide; 8-[(cycloheptylmethyl-amino)-methyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide; 8-{[cyclopropylmethyl-(3-methyl-butyl)-amino]-methyl}-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide; 8-[2-(4-chloro-phenyl)-pyrrolidin-1-ylmethyl]-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide; 8-(2-phenyl-azepan-1-ylmethyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide; and 8-(2-benzyl-pyrrolidin-1-ylmethyl)-10,11-dihydro-dibenzo[b,f]oxepine-2-carboxylic acid amide;
or a pharmaceutically acceptable salt or solvate thereof.